133 results about "Novel virus" patented technology

The invention provides novel use of a cyanine dye in the detection of a G-quadruplex DNA. The detection of the G-quadruplex DNA by using the cyanine dye has the advantages of simplicity, quickness and relatively low prices and overcomes the drawbacks of the prior detection technology such as long period, high price and high technical and equipment requirements. The use of the cyanine dye in the detection of the G-quadruplex DNA makes whether a DNA sample in solution has a G-quadruplex structure or a linear double helical structure determined quickly by a UV-visible absorption spectrum, fluorescence spectrum or confocal laser scanning microscopy. By using confocal laser scanning microscopy, the DNA sample assembled on the surface of Au can be marked visually, so the structure of the DNA sample can be recognized and the specific assembly position of the DNA sample on the surface of the Au can be marked at the same time.

The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention provides the nucleic acids and peptides encoded by and/or derived from the hSARS virus and their use in diagnostic methods and therapeutic methods, including vaccines. In addition, the invention provides chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies immunospecific to the polypeptides encoded by the nucleotide sequences.

The present invention relates to isolation and characterization of a class of isolated novel viruses which is the precursor of the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The precursor virus which is a SARS coronavirus-like virus (“SCoV-like virus”) is identified to be morphologically and phylogenetically similar to hSARS virus. The present invention relates to a nucleotide sequence comprising the genomic sequence of the SCoV-like virus. The invention further relates to nucleotide sequences comprising a portion of the genomic sequence of the SCoV-like virus. The invention also relates to the deduced amino acid sequences of the SCoV-like virus. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies directed against polypeptides encoded by the nucleotide sequences. Furthermore, the invention relates to vaccine preparations comprising the SCoV-like virus, including recombinant and chimeric forms of said virus.

The present invention provides novel virus vaccines with augmented, e.g., enhanced and/or extended immunogenicity. The virus vaccines of the invention comprise an envelope-bound immunomodulatory protein, e.g., a cytokine, chemokine or costimulatory molecule. The immunomodulatory protein serves as an adjuvant to augment, e.g., enhance or extend the immunogenicity of the virus vaccine, thereby augmenting, e.g., enhancing or extending immune response to the virus when administered to a subject.

The invention relates to virus-like particle recombinant protein of a virus variation strain VP2 gene of an infectious bursal disease, belonging to the field of biologic pharmacy. The IBDV variation strain (AH1) VP2 gene is cloned, converted and transfected to obtain a recombinant baculovirus vBac-VP2; an infected Sf9 insect cell has specific fluorescence, and the antigen valence of the infected Sf9 insect cell is above 1.6*10<3>; the molecular weight of a recombinant VP2 protein is 53kDa, and the recombinant VP2 protein is in the state of virus-like particles; an indirect ELISA detection method established for an envelope antigen by the purified recombinant VP2 protein has good specificity and sensibility; an immune chicken can resist IBDV virulent attack, and the protection ratio achieves 100 percent. The novel virus-like particle recombinant VP2 protein prepared by the IBDV variation strain VP2 gene has high pertinence on the immune prevention of a current prevalent IBDV virulent strain and good practical value and popularization prospects.

The invention provides a novel viral vaccine for treating a non-small cell lung cancer and a preparation method thereof. The preparation method of the viral vaccine comprises the first step of constructing a carrier of an MVA virus and the second step of obtaining specificity presenting MAGE-3 antigen DC cells. According to the viral vaccine prepared through the method, the biological stability is high, adverse effects on human bodies are not produced, and pathogenic dangers do not exist; a virus antibody can obtain a large number of viral particles with high purity easily; MAGE-A3 expressed by the viral vaccine has better immunogenicity, more epitopes are achieved, and drug resistance is not prone to being caused; the viral load needed in inoculation of the viral vaccine is smaller than other viruses.

The invention discloses a late promoter targeting adjustment and control oncolytic adenovirus pCN305 vector, a construction method and application thereof. The vector is established on a pCN103 vector with targeting property; all exogenous genes for killing and inhibiting various cancers, such as IL-24, TRAIL, SOCS3, cpp-SOCS3, SOCS1, cpp-SOCS1and so on, are adjusted, controlled and expressed by late promoters of viruses through induction of internal ribosome into IRES sites and polyclonal sites; and the pCN305 vector has good anticancer effect through experiment in vivo and vitro. All double-target replicating oncolytic adenovirus established by application of the pCN305 vector, such as AdCN305-IL-24, AdCN305-TRAIL, AdCN305-SOCS3, AdCN305-cpp-SOCS3, AdCN305-SOCS1, AdCN305-cpp-SOCS1 and so on, can be used for treating various tumors. Moreover, the invention can develop a novel virus-gene anticancer medicine for effectively treating the tumors.

The invention aims at providing an H9 subtype avian influenza virus strain. Vaccine is prepared by the virus strain to solve the problem that existing H9 subtype avian influenza virus vaccine is poor in immune effect caused by a novel virus. The H9 subtype avian influenza virus QDY strain (Avian Influenza Virus) is preserved in the typical culture preservation center in China in Wuhan University on April 29, 2015, and the preservation number is CCTCC NO: V201517. After the H9 subtype avian influenza virus (QDY strain) is inoculated to a chick embryo, a virus solution is collected, after ultrafiltration concentration and formaldehyde solution inactivation are performed, oil adjuvant is added, and then mixing and emulsifying are performed to prepare the vaccine. According to the prepared vaccine, the antibody level after immunization can be improved, the antibody uniformity after immunization can be improved, and the immune effect of the vaccine can be guaranteed; the vaccine has the advantages of being efficient and good in safety.

The invention discloses a detection method for identifying the American classical PRRSV strain, the HP-PRRSV strain and a new-type viral NADC30 strain at the same time. In the method, a multiplex real-time fluorescence RT-PCR for identifying three kinds of strains at the same time is established based on an ABI7500 fluorescent quantitative PCR instrument, wherein the strains include the classical PRRSV strain, the highly-pathogenic HP-PRRSV strain with the deletion of L-amino acid at the 481st locus of the Nsp2 gene and the continuous deletion of 29 amino acids at the 533ird-561st loci of the Nsp2 gene, and NADC30like; specific primers and specific probes for the three kinds of strains are designed respectively based on the Nsp2 gene, universal primers and universal probes for PRRSV are designed according to the relatively conserved N gene, missing detection caused by Nsp2 region mutation can be effectively prevented, and false negative can be avoided.

The invention relates to the field of computers, in particular to a method and device for detecting baleful programs. The method and device are used for improving the searching and killing capacity to novel viruses. The method includes the steps that program samples are put in a sandbox system to run, various associated processes generated by the program samples are monitored in real time, authority state information of the associated processes is recorded, and when it is determined that the authority of any associated process is improved, it is judged that the program samples are the baleful programs. Thus, baleful program detection can be carried out without depending on known security flaw characteristics, even aiming at new advanced threats, the program samples can be accurately defined as baleful programs, and the detection success rate of unknown viruses is greatly increased.

The invention relates to respiratory syncytial virus-like particles, and establishes a novel method of preparing respiratory syncytial virus-like particles for animal immunization. The preparation method comprises the following steps: according to codon bias of mammalian cells, carrying out codon optimization for M, F and G genes which are respectively cloned to a shuttle vector to obtain recombinant adenovirus plasmids, and transfecting to obtain the recombinant adenovirus FGAd-Msyn, FGAd-Fsyn and FGAd-Gsyn; infecting the recombinant adenovirus by use of Vero cells to obtain the virus-like particles; purifying the virus-like particles by adopting a sucrose density gradient centrifugation method; applying the particles to animal immunization. According to the invention, the virus-like particles are prepared by adopting the adenovirus vector, and a novel virus-like particle preparation method is established. The protein expression quantity is improved and the yield of the virus-like particles is improved through codon optimization, so that a better immune effect is obtained, and the respiratory syncytial virus-like particles are relatively safe.

In the right formula, R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ , R ⁷ , R ⁸ , R ⁹ and A each have the same meaning as given in the specification. A method wherein pyrazine nucleoside analogs [2] and pyrazine nucleoside analogs [3z] are converted in vivo, and further decomposed and phosphorylated into pyrazines having virus growth inhibitory activity and/or virucidal activity Nucleotide analogs [1b]. The method can be used as a method for treating viral infection diseases. Furthermore, the pyrazinecarboxamide analogue or salt thereof of the present invention can be used as an agent for the prevention/treatment of viral infection.

The invention discloses a novel coronavirus 2019-nCoV nucleic acid kit and a virus nucleic acid acquisition method. The method comprises the following steps: according to novel coronavirus 2019-nCoV ORF1ab and an N gene as amplification target areas, designing specific primers and fluorescent probes for detecting novel coronavirus 2019-nCoV nucleic acid in samples; and performing Digital PCR (polymerase chain reaction) absolute quantification on 2019-nCoV nucleic acid RNA (ribonucleic acid) by using a one-step method by using a prepared Super premix reaction liquid A together with Super premixreaction liquids B and C, and performing Digital PCR detection on RNA of a diluted positive virus sample. The kit and the method have the beneficial effects that by using the novel virus nucleic acidacquisition method, and together with a Digital PCR probe method, the nucleic acid positive detection rate of infection of the novel coronavirus 2019-nCoV can be increased, the process is ensured tobe specified and standardized, the influence of artificial non-standard operation upon detection results can be reduced, result reliability can be ensured, and meanwhile, false negative results causedby detection of sputum and throat swab sampling together with real-time fluorescent PCR methods can be avoided.

The invention discloses a Serverless framework-based multi-engine virus scanning system and multi-engine virus scanning method. The multi-engine virus scanning system comprises a mobile terminal and aServerless cloud network; the mobile terminal comprises a client; the Serverless cloud network comprises a virus engine router and a Serverless scanning cluster; the client is used for uploading to-be-detected files; the virus engine router is used for receiving the to-be-detected files and distributing the to-be-detected files to containers in the Serverless scanning cluster in sequence according to a preset task distribution algorithm; the containers are used for performing virus scanning on the received to-be-detected files by utilizing the corresponding virus scanning engines and sendingscanning results to the virus engine router; and the virus engine router is further used for summarizing the scanning results and generating corresponding final scanning result information. Accordingto the technical scheme, the consumption of calculation resources and power resources of the mobile terminal can be greatly reduced; and the virus searching and killing range and accuracy and the novel virus response speed are improved and increased.

The present invention provides yeast-expressed Coxsackievirus A10 virus-like particles and applications thereof. According to the present invention, specifically the gene sequences of the P1 protein and the 3CD protein of Coxsackievirus A10 are transformed into yeast cells, and expression is performed to obtain the novel Coxsackievirus A10 virus-like particles; and the yeast-expressed Coxsackievirus A10 virus-like particles have characteristics of high expression, strong immunogenicity and good specificity.

This invention relates to the isolation and uses of novel avian astroviruses. The present invention also relates to vaccines, kits and methods for detection of a novel astrovirus. The present invention further relates to vaccination of avians, prevention and/or treatment of avian infections associated with astrovirus. Infections of poultry by this novel astrovirus are associated with runt stunting syndromes.

A novel use of GRP 94 in treatment of virus infection is provided. More specifically, a method of inhibiting virus infection by inhibiting expression of GRP 94 and/or inactivating activity of GRP 94, and a method of developing drugs for preventing and/or treating virus infection and/or diseases caused by virus infection by using GRP 94 as a target are provided.

The invention provides a fluorescently-labeled porcine reproductive and respiratory syndrome virus and a building method and application thereof and belongs to the technical field of gene engineering. The building method is characterized in that a fluorescence labeling expression box with a fluorescence labeling gene is connected to a connection site on an infectious clone plasmid to obtain the visual fluorescently-labeled porcine reproductive and respiratory syndrome virus, and the connection site is located between the downstream of an N protein gene sequence and the upstream of a 3' end noncoding sequence. The building method is low in operation difficulty, high in operability and capable of acquiring the fluorescently-labeled porcine reproductive and respiratory syndrome virus capable of stably expressing fluorescent protein and provides a powerful tool for further carrying out novel virus vaccine development and basic researches related to the porcine reproductive and respiratory syndrome virus.

The invention discloses a novel EV71 virus strain of which the whole-genome length is 7405bp and the sequence is shown in SEQID NO:1. The virus strain can infect ICR, KM, BALB/c and NIH mice; the virus dosage of larger than 1*10<2>-1*10<7> TCID50 can cause the disease attack or death of 1-17 days mice; the administration route can be intraperitoneal injection, encephalocoele injection and intragastric administration; the symptoms are typical symptoms of EV71 virus infection and are divided into the following five levels according to stages of the disease: Level 0: not attacked; L1: motion incoordination and weakness of limbs; L2: hypokinesia and paralysis of fore or posterior limbs; L3: quadriplegia and dying; and L4: death. Various animal evaluation models such as an immunogenicity animal evaluation model of hand-foot-and-mouth disease vaccine and an animal evaluation model of EV71 therapeutic drug and therapeutic vaccine, can be built conveniently.

The invention discloses a method for efficiently producing recombinant avian adeno-associated virus. The method comprises the steps of first respectively constructing recombinant baculovirus rBacRep for expressing functional protein genes Rep78 and Rep52 of avian adeno-associated virus (AAAV), recombinant baculovirus rBacVP for expressing three structural protein genes VP1, VP2 and VP3 of the AAAV and recombinant baculovirus rBacGFP for expressing green fluorescence protein reporter genes; infecting insect cells Sf9 with the rBacRep, the rBacVP and the rBacGFP simultaneously, and obtaining rAAAV-GFP. According to fluorescent quantitative polymerase chain reaction (PCR) detection, each Sf9 cell can generate about 28000 VG of rAAAV-GFP, and the yield is improved by about 20 times compared with a conventional three-plasmid method. The method not only is simple and convenient in operation procedure and greatly improves virus titer, but also is easy to produce in a large scale, and the bottleneck of using rAAAV as a novel virus gene transfer vector is overcome.